Background Skeletal muscle glucose utilization is an important component of whole-body glucose consumption in normal humans. Fluorine-18-labelled fluoro-2-deoxy-d-glucose ( 18 F-FDG) is a non-invasive molecular imaging probe for evaluating
Introduction
The increasing prevalence of metabolic diseases with advancing age is a major public health concern worldwide. It is well known that both skeletal muscle volume 1,2 and quality are key determinants of the risk of metabolic abnormalities.
1
Skeletal muscle glucose utilization (SMGU) accounts for 70-80% of whole-body glucose consumption in normal humans and is thought to be the most important determinant of whole-body insulin resistance (IR).
3
Fluorine-18-labelled fluoro-2-deoxy-d-glucose ( 18 F-FDG), a glucose analog, is a non-invasive molecular imaging probe that is used for quantitative in vivo evaluation of glucose utilization in tissues and whole organs.
18
F-FDG positron emission tomography/computed tomography (PET/CT) has been used widely for evaluation of neoplastic diseases [4] [5] [6] [7] and less commonly for non-neoplastic inflammatory diseases, 7, 8 as well as for risk stratification in patients with carotid atherosclerosis.
9-12
The utility of 18 F-FDG uptake as a biomarker for metabolic derangement is unclear. Previous reports using this probe provided valuable insights into IR, and it has been used to measure SMGU in vivo. 3, [13] [14] [15] [16] The rate of glucose disposal during the hyperinsulinemic euglycemic clamp test was correlated with SMGU estimated by dynamic or static 18 F-FDG PET.
3,13-16
However, previous studies had small sample sizes and were experimental; therefore, clinical assessments are needed. We investigated the biodistribution of 18 F-FDG in insulinsensitive organs, including the liver, skeletal muscle, and fat tissue, to relate this marker to metabolic derangement in an average-risk population. We also aimed to validate 18 F-FDG uptake of insulin-sensitive organs as a surrogate marker to predict MetS.
Research design and methods

Study design
In a single centre, we retrospectively reviewed the records of 18 F-FDG PET/CT assessments that were included in routine wellness check-ups. The dataset comprised an experimental and a validation group. Between January and December 2014, 196 subjects underwent 18 F-FDG PET/CT. Thirty-nine were excluded for one or more of the following reasons: positive serologic markers for hepatitis B virus surface antigen or hepatitis C antibody, a history of taking herbal medicines, steroids, or amiodarone (all of which are known to cause fatty liver) in the previous month, and suspicion of a malignant tumour on abdominal ultrasonography. Subjects who received anti-diabetic drugs, cholesterol-lowering agents, and antihypertensive drugs were included in the study. Finally, 157 subjects (91 men and 66 women; mean age 49.9 ± 11.1 years) constituted the experimental group (cross-sectional cohort).
We retrospectively reviewed subjects who had one or more follow-up health checks after 18 F-FDG PET/CT scans, between January 2009 and December 2012. The exclusion criteria were same as those in the experimental group, yielding a total of 158 subjects (91 men and 67 women; mean age 52.6 ± 7.9 years) with complete records of the required clinical parameters. These subjects comprised the validation group (longitudinal cohort) ( Table 1) . The study protocol was reviewed and approved by the institutional review board at our institution (approval number HYIRB 2015-10-006-001). 
Biochemical analyses
After an overnight fast, peripheral blood was drawn from an antecubital vein to measure fasting blood glucose (mg/dL), triglyceride (mg/dL), total cholesterol, low-density lipoprotein (mg/dL), HDL (mg/dL) cholesterol, aspartate aminotransferase (U/L), alanine aminotransferase (U/L), bilirubin (mg/dL), and γ-glutamyl transferase (U/L).
Fluorine-18-labelled fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging and analysis ) were manually drawn over the anterosuperior and posteroinferior portions of the right lobe of the liver, carefully avoiding the central vascular area. These two values were averaged to estimate the mean SUV (SUV mean ) of the liver. For the psoas muscle and subcutaneous fat, two fixed VOIs 3 cm in diameter (volume, 14.13 cm 3 ) were manually drawn over the right psoas muscle and subcutaneous layer of the right gluteal area to assess the maximum SUV (SUV max ) of each VOI. For the pancreas and mesenteric visceral fat, two small and flexible VOIs were drawn over the pancreas tail and retroperitoneal area around the right kidney, avoiding small vessel activity, to assess the SUV max of each VOI.
Statistical analyses
Continuous data are presented as means ± SD or medians (Q 1 -Q 3 ) and compared between groups using either Student's t-tests or Mann-Whitney U tests as appropriate, following normality tests. Categorical data are presented as frequencies (%) and compared using chi-squared tests. In the experimental group, correlation analysis using Spearman rank correlation coefficients and simple and multiple logistic regression analyses were used to identify independent predictors of MetS.
The areas under the receiver operating characteristic (AUROC) curves were estimated to assess discriminative ability, and AUROC based on psoas muscle was compared with other potential predictors using pairwise Z-tests with Bonferroni corrections. The known cut-off values were adopted for given clinical predictors, whereas optimal cutoff values were determined for PET/CT predictors to maximize the value of the Youden index for the receiver operating characteristic curve. The sensitivity, specificity, accuracy, and positive and negative predictive values (PPV and NPV) were calculated and compared between the psoas muscle and other predictors using post hoc comparisons with Bonferroni correction after Cochran's Q or chi-squared tests.
Finally, new-onset event-free MetS survivors and subjects with other metabolic derangements indicated by optimal cut-off values of SUV max in the psoas muscle group were assessed using Kaplan-Meier survival analysis and compared using the log-rank test. Also, multiple Cox's proportional hazard regression analyses were performed for the psoas muscle groups to assess the independent predictors of the presence or absence of these new-onset events. P-values <0.05 were considered statistically significant. All statistical analyses were performed using SAS 9. 
Results
Correlation between fluorodeoxyglucose uptake of various organs and metabolic parameters
uptakes in psoas muscle, mesenteric visceral fat, abdominal subcutaneous fat, pancreas, and liver were all positively correlated with waist circumference, body mass index (BMI), systolic and diastolic pressures, and fasting glucose (this last with the exception of pancreas) ( Table 2) . Among these, 18 F-FDG uptake (SUV max ) of psoas muscle showed the strongest correlation with these clinical metabolic parameters in the experimental group.
Fluorodeoxyglucose uptake of psoas muscle as an independent risk factor for metabolic syndrome
Simple and multiple logistic regression analyses identified SUV max of the psoas muscle in the experimental group as an independent risk factor for MetS [adjusted odds ratio (OR) 49.21; 95% confidence interval 1.12-999.99; P = 0.044] after adjusting for age, waist circumference, BMI, triglycerides, HDL cholesterol, systolic and diastolic pressure, and fasting glucose ( Table 3) .
Assessment of areas under the receiver operating characteristic and cut-off value of maximum standardized uptake value for psoas muscle and predictive performance for metabolic syndrome in the experimental group
The SUV max of the psoas muscle had the highest AUROC value, identifying it as a significant predictor of existing MetS (0.779, Figure 1A) . As a predictor of MetS, SUV max of the psoas muscle (0.779, cut-off at 1.34) was comparable to the AUROCs among other clinical predictors. There were no significant differences among metabolic risk factors: BMI (0.837, cut-off at 25 kg/m2), triglyceride (0.904, cut-off at 150 mg/dL), HDL cholesterol (0.755, cut-off at 40 mg/dL in men and at 50 mg/dL in women), systolic pressure (0.742, cut-off at 130 mmHg), and fasting glucose (0.839, cut-off at 110 mg/dL) ( Figure 1B) . In the experimental group, when the cut-off SUV max for psoas muscle was set at 1.34, the sensitivity, specificity, accuracy, PPV, and NPV for predicting MetS were 70.0%, 84.6%, 80.9%, 60.9%, and 89.2%, respectively. Relative to the diagnostic values of clinical predictors (BMI, triglyceride, HDL cholesterol, systolic pressure, diastolic pressure, and fasting glucose), the specificity and accuracy of psoas muscle metabolism in the prediction of MetS was significantly higher than those of BMI and systolic pressure ( Table 4) .
Assessment of predictive performance for metabolic syndrome in validation group
We applied this cut-off (1.34) SUV max for psoas muscle in the validation group to confirm its feasibility and reliability. The AUROC value for prediction of MetS was 0.709, and the sensitivity, specificity, accuracy, PPV, and NPV for predicting MetS were 47.6%, 92.3%, 86.1%, 50.0%, and 91.6%, respectively. Again, relative to the diagnostic values of clinical predictors (BMI, triglyceride, HDL cholesterol, systolic pressure, diastolic pressure, and fasting glucose), the specificity of psoas muscle metabolism as a predictor of MetS was higher than those of BMI, systolic pressure, and fasting glucose; its accuracy was higher than that of BMI ( Table 5) .
In subjects with SUV max > 1.34 in the psoas muscle, the prevalence rates for metabolic abnormalities were significantly higher than those in subjects with SUV max ≤ 1.34 in the psoas muscle in both the experimental group (Table S1 ) and the validation group (Table S2) .
Survival analysis for incipient metabolic syndrome and its determinants in the validation group
The median duration of follow-up in the validation cohort was 2.25 years. The Kaplan-Meier curve showed that the cumulative incidence of new onset MetS (Figure 2A ) and other clinical risk parameters for MetS ( Figure 2B ) was significantly higher in subjects with higher psoas muscle uptakes of 18 F-FDG (SUV max > 1.34) than in those with lower values (SUV max ≤ 1.34) (log-rank test for MetS, P = 0.0093; HDLcholesterolemia, P < 0.0001; hypertension, P = 0.0001; hyperglycaemia, P = 0.0458). In a Cox proportional hazards model adjusted for age and sex, 18 F-FDG uptake (SUV max ) in the psoas muscle was associated with increased risks of incipient MetS [hazard ratio (HR) 3.26, P = 0.0174], low HDL Figure 1 Comparisons of receiver operating characteristic (ROC) curves and the areas under the receiver operating characteristic (AUROC) among (A) Fluorodeoxyglucose uptake of insulin sensitive organs on fluorine-18-labeled fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography and (B) other clinical predictors and fluorodeoxyglucose uptake of psoas muscle for the discrimination of metabolic syndrome (MetS) in experimental group. * Significant difference by pairwise Z-test with Bonferroni correction with respect to psoas muscle (P < 0.05). † Cut-off value is determined to maximize the value of Youden index for ROC curve using Medcalc. BMI, body mass index; HDL, high-density lipoprotein; SubQ, subcutaneous; TG, triglyceride. Cut-off value is determined in the experimental group to maximize value of the Youden index for the ROC curve using Medcalc. Figure 2 Kaplan-Meier estimator plot of cumulative incidence for (A) metabolic syndrome and (B) risk determinants of metabolic syndrome in the two subgroups according to fluorodeoxyglucose uptake of psoas muscle (cut-off value of maximum standardized uptake value = 1.34). Significant differences were observed between the two subgroups (for all P < 0.05, except for hypertiglyceridemia). F-FDG uptake (SUV max > 1.34) in the psoas muscle showed a higher prevalence of existing MetS, and these patients also had significantly higher incidences of incipient MetS during clinical follow-up periods than did subjects with lower 18 F-FDG uptake (SUV max ≤ 1.34). Therefore, the
18
F-FDG uptake value in psoas muscle could be used as a valuable surrogate marker to predict metabolic derangement in clinical circumstances.
18 F-FDG is mainly taken up by glucose transporter type 4 (GLUT4) proteins in muscle. Glucose transport is a rate-limiting step for insulin-stimulated glucose utilization in skeletal muscle. 18, 19 It is well known that GLUT4 is essential for insulin-mediated glucose transport in insulin-sensitive organs, including skeletal muscle, adipose tissue, and the heart. 20, 21 The majority of insulin-dependent postprandial glucose uptake occurs in the skeletal muscle, and it is believed that IR on the part of GLUT4 in muscle plays a central role in the development of type 2 diabetes. F-FDG uptake in the psoas muscle. Second, dynamic PET imaging for kinetic analysis may have allowed accurate in vivo assessment of glucose transport and phosphorylation.
28,29 However, we used static PET imaging, which is more convenient for clinical application in a large-scale clinical study. Third, some studies have shown that GLUT expression may be increased on the surface of recruited macrophages and hypertrophied adipocytes and mediated by chronic low-grade inflammation in obese patients. 30, 31 We did not do psoas muscle biopsies so did not check inflammatory cell infiltration in this muscle.
In conclusion, increased 18 F-FDG uptake in the psoas muscle successfully identified subjects with a significantly increased risk of incipient metabolic derangement and MetS, even though these individuals were not clinically classified with MetS at present.
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